South Dakota Investment Council Sells 12,800 Shares of Solventum Corporation $SOLV

South Dakota Investment Council lowered its stake in Solventum Corporation (NYSE:SOLV) by 5.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 242,825 shares of the company’s stock after selling 12,800 shares during the period. South Dakota Investment Council owned approximately 0.14% of Solventum worth $17,726,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in Solventum by 5.3% in the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock valued at $1,249,847,000 after purchasing an additional 867,837 shares during the last quarter. Independent Franchise Partners LLP increased its stake in shares of Solventum by 74.2% in the second quarter. Independent Franchise Partners LLP now owns 10,141,066 shares of the company’s stock worth $769,098,000 after buying an additional 4,320,342 shares during the period. Davis Selected Advisers raised its holdings in Solventum by 3.9% during the 2nd quarter. Davis Selected Advisers now owns 5,492,661 shares of the company’s stock valued at $416,563,000 after buying an additional 204,523 shares during the last quarter. Boston Partners boosted its position in Solventum by 9.2% during the 2nd quarter. Boston Partners now owns 3,670,757 shares of the company’s stock valued at $278,363,000 after buying an additional 308,784 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Solventum by 1.0% in the 2nd quarter. Geode Capital Management LLC now owns 3,563,792 shares of the company’s stock worth $269,116,000 after acquiring an additional 36,660 shares during the last quarter.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Mizuho set a $100.00 price objective on shares of Solventum and gave the company an “outperform” rating in a research note on Tuesday, January 20th. KeyCorp upped their price target on Solventum from $97.00 to $99.00 and gave the company an “overweight” rating in a research report on Friday. UBS Group reiterated a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Wall Street Zen raised Solventum from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, BTIG Research reaffirmed a “buy” rating and issued a $100.00 price target on shares of Solventum in a research note on Friday. Seven analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $93.70.

Solventum Stock Down 1.6%

Shares of NYSE:SOLV opened at $73.05 on Tuesday. The stock has a fifty day simple moving average of $78.43 and a two-hundred day simple moving average of $76.24. The stock has a market capitalization of $12.67 billion, a price-to-earnings ratio of 8.24, a PEG ratio of 6.75 and a beta of 0.40. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $88.20. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last announced its quarterly earnings results on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. The company had revenue of $2 billion for the quarter, compared to analysts’ expectations of $1.96 billion. Solventum had a net margin of 18.69% and a return on equity of 25.26%. Solventum’s revenue was down 3.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.41 EPS. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, research analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its Board of Directors has approved a stock repurchase plan on Thursday, November 20th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 7.5% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.